Reanalysis of UK22 subcutaneous immunotherapy trial according to WAO/EAACI 57 recommendations revealed clinically relevant improvements at both doses. Starting at the lower 58 dose should enable efficacy with lower risk of adverse events. 59
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Indoor Biotechnologies, grants from Glaxo Smith Kline, outside the submitted work. Subcutaneous immunotherapy (SCIT) is widely used for therapy of patients with allergic 64 rhinoconjunctivitis, with or without allergic asthma [1] [2] [3] . The strength of clinical evidence 65 supporting this treatment varies between different allergen immunotherapy (AIT) products. In 66 addition AIT products are not directly comparable as they differ in allergen content, allergen 67 structure (chemically modified allergens/intact allergens), adjuvants used or application 68 formulations. Consequently, clinical efficacy must be documented individually for each product 69
The efficacy of Alutard SQ ® Phleum pratense (ALK, Denmark) for allergen immunotherapy for 71 grass pollen allergic patients has been demonstrated in several controlled clinical trials with adults 72 and children [4] [5] [6] [7] , both with the maximum dose for maintenance treatment 100,000 SQ-U, and 73 also with a lower dose of 10,000 SQ-U [4]. Supplementary references on clinical trials with the 74 product and identical manufactured products can be found in the online repository. 75
In a large randomized, double blind, placebo-controlled clinical trial in 26 UK hospital clinics 76 conducted in 2002, the UK22 trial, subjects were randomized in a 1:1:2 ratio to receive placebo, 77
Alutard SQ Phleum pratense 10,000 SQ-U or 100,000 SQ-U as maintenance dose. Details of 78 inclusion and exclusion criteria, subject characteristics, dosage schedules and the individual 79 primary and secondary outcome parameters have been published previously [4] . As (co-)primary 80 endpoints symptom scores and medication use were evaluated separately. While the symptom 81 scores were significantly lower compared with placebo for both doses, the medication scores were 82 statistically significantly decreased only with the higher dose (100,000 SQ-U). Responders to AIT 83 were 76.7% of subjects with 100,000 SQ-U, 66.3% with 10,000 SQ-U and 55.0% with placebo 84 according to subjective evaluations of symptoms (subjects who reported improvement compared to 85 previous years, see Table 1 in the Online repository). There was a clear dose-dependent effect 86 on the responder rate -the surprisingly high placebo responder rate was likely a result of the
The tolerability of treatment was also dose-dependent, with fewer adverse events on the 10,000 89 SQ-U maintenance dose, although local and delayed side effects were generally mild. Clinically 90 significant early and delayed systemic side effects were confined to the 100,000 SQ-U group. In 91 this group urticaria or asthma graded as early non-life threatening grade 3 reactions according to 92 the European Academy of Allergy and Clinical Immunology (EAACI) grading scheme were 93 reported in 4.4% of subjects, and urticaria, wheezing, asthma and angioedema as delayed 94 systemic reactions graded mild in 14% of subjects and severe in 2% [4]. This is in line with results 95 from other trials with the 100,000 SQ-U maintenance dose [5] [6] [7] . 96
After completion of the UK22 trial a World Allergy Organization (WAO) task force [8] recommended 97 to combine symptom scores and medication scores as key primary endpoints in AIT trials, and in a 98 recent Position Paper of the EAACI, [9] a consensus definition for the combined symptom and 99 medication score (CSMS) has been published. The CSMS used as the primary outcome parameter 100 for efficacy in clinical trials of AIT equally takes into account both the severity of symptoms and the 101 need for anti-allergic medication. A very important aim of this recommendation by international 102 experts in AIT was to standardize the clinical endpoints of AIT trials internationally and, thereby, to 103 improve the quality and comparability of AIT trials [9] . 104
We have applied this principle to the UK22 trial [4] and reanalyzed the trial data post-hoc by 105 calculating a composite score for symptoms and medication usage. In the UK22 trial nasal, eye 106 and lung symptoms were recorded on daily diary cards using a 4-point scale (none, mild, 107 moderate, severe) to assess the daily symptom score. The daily medication score had been 108 More details on the statistical methods can be found in the online repository. 116
The composite combined scores evaluated over the whole season in the reanalysis were 117 significantly reduced compared with placebo (6.85 score points) both for the 100,000 SQ-U group 118 (by 2.47 score points (p<0.0001) with a relative difference of 36.06% to Placebo), and for the 119 10,000 SQ-U group (by 1.70 score points (p=0.0098) with a relative difference of 24.85% to 120 Placebo), (Fig 1) . These changes were not statistically different between the two immunotherapy 121 groups. of 10,000 SQ-U for which a clinically relevant effect has been proven in this study. If patients 130 remain unacceptably symptomatic during the first grass pollen season after start of AIT they could 131 be considered to be further up-dosed to 100,000 SQ-U to achieve an increased clinical effect. With 132 this approach it may be possible to achieve an optimal outcome for patients taking into account 133 both tolerability and clinical effectiveness. 
Details of statistical methods 2

Treatment was handled as a fixed class effect and Region as a random class variable. 3
Different residual errors for each treatment group were specified in the LME model. Each of the 4 two active dose groups (100,000 SQ-U and 10,000 SQ-U) was compared to placebo using a t-test 5 in the LME model. Adjusted means and the difference in adjusted means for each active dose 6 group compared to placebo (placebo-active) were calculated together with the associated 95% 7 confidence intervals. The relative differences of the adjusted means were also reported with 95% 8 confidence limits, calculated based on Fieller's theorem. 
grass and/or birch allergens [4] with high risk of bias according to the EAACI Guidelines on AIT in 19
Allergic Rhinitis and Allergy Prevention [2, 5] . 20
The efficacy of a maximum dose equivalent to 10,000 SQ-U (1,000 SE-U) has been demonstrated 21 for the first pollen season after treatment in randomized double-blind placebo-controlled trials with 22 an identically manufactured product (ALK7) containing grasses, rye [4] and tree allergens [5] with 23 high quality and low risk of bias according to the EAACI Guidelines on AIT in Allergic Rhinitis [2] . 
